1.中山市中智药业集团有限公司,广东 中山 528437
2.中山市恒生药业有限公司,广东 中山 528411
乔卫林,硕士,高级工程师,研究方向:中药新药及中药质量,E-mail:weilin_qiao@126.com
扫 描 看 全 文
乔卫林,张礼行,彭丽华等.壮腰健肾片的物质基础及质量标准提升研究[J].分析测试学报,2023,42(04):402-410.
QIAO Wei-lin,ZHANG Li-hang,PENG Li-hua,et al.Study on the Material Basis and Quality Standard Improvement of Zhuangyao Jianshen Tablets[J].Journal of Instrumental Analysis,2023,42(04):402-410.
乔卫林,张礼行,彭丽华等.壮腰健肾片的物质基础及质量标准提升研究[J].分析测试学报,2023,42(04):402-410. DOI: 10.19969/j.fxcsxb.22120603.
QIAO Wei-lin,ZHANG Li-hang,PENG Li-hua,et al.Study on the Material Basis and Quality Standard Improvement of Zhuangyao Jianshen Tablets[J].Journal of Instrumental Analysis,2023,42(04):402-410. DOI: 10.19969/j.fxcsxb.22120603.
应用超高效液相色谱-四极杆飞行时间质谱联用(UPLC-Q-TOF MS,E,)技术及UNIFI软件分析和识别壮腰健肾片的化学成分,运用ADMETlab、TCMSP数据库预测和筛选活性成分,共筛选出55个潜在活性成分。在活性成分分析的基础上,结合与壮腰健肾片功能主治相关的药理活性文献报道进行综合评估,确认以没食子酸、原儿茶酸和原儿茶醛为含量测定指标。建立了壮腰健肾片中上述3种成分含量的高效液相色谱(HPLC)测定方法,并对15批次样品进行测定,测得没食子酸、原儿茶酸、原儿茶醛的含量分别为0.135 3 ~ 0.344 8、0.430 8 ~ 0.946 3、0.042 4 ~ 0.107 7 mg/g。进一步建立了壮腰健肾片的HPLC指纹图谱,确定15个共有峰并归属至处方药味,15批样品的相似度为0.988 ~ 1.000,批次间的成分一致性较高。该研究新建立的分析指标较原标准能更全面地表征及评价壮腰健肾片的质量,可为该制剂的药效物质基础分析和质量标准提高提供科学依据,对提高产品的质量可控性具有重要意义。
An ultrahigh performance liquid chromatography-quadrupole time-of-flight mass spectrometry(UPLC-Q-TOF MS,E,) with UNIFI software analysis was used to analyze the chemical components in Zhuangyao Jianshen tablets.The active components were screened by ADMETlab and TCMSP database,of which 55 potential active components were found.The galic acid,protocatechuic acid and protocatechuic aldehyde were determined as the content determination index,based on the comprehensive evaluation of active components and the pharmacological activity literature related to the function of Zhuangyao Jianshen tablets.Meanwhile,a high performance liquid chromatography(HPLC) method was established to detect the contents of galic acid,protocatechuic acid,protocatechuic aldehyde in 15 batches of samples,which were 0.135 3-0.344 8 mg/g,0.430 8-0.946 3 mg/g and 0.042 4-0.107 7 mg/g,respectively.The HPLC fingerprints for 15 batches of Zhuangyao Jianshen tablets were established,15 common peaks were calibrated and attributed to the Chinese medicine of the prescription with their similarities between 0.988 and 1.000,which showed that the inter-batch consistency of ingredients were high.Compared with those in the original standard,the newly established analytical indexes in this paper could more comprehensively characterize and evaluate the quality of Zhuangyao Jianshen tablets,and provide a scientific basis for the effective material analysis and the improvement of the quality standard.It is of great significance to improve the quality controllability of the product.
壮腰健肾片超高效液相色谱-四极杆飞行时间质谱联用物质基础质量标准指纹图谱含量测定
Zhuangyao Jianshen tabletsUPLC-Q-TOF MSEmaterial basisquality standardfingerprintcontent determination
Chinese Pharmacopoeia Commission. Drug Standards of the Ministry of Health of the People’s Republic of China.Tradi-tional Chinese Medicine Prescription Preparation(13 th). Beijing:People’s Medical Publishing House(国家药典委员会.中华人民共和国卫生部药品标准·中药成方制剂.第十三册.北京:人民卫生出版社),1997:73.
Hu J,Hu Z Z.J. Youjiang Med. Univ. Natl. (胡建,胡忠泽.右江民族医学院学报),2021,43(4):460-464.
Luo H W.Chin. Mod. Med. (罗华文.中国当代医药),2018,25(6):94-95.
Tao X H,Xue L X,Liu C.China’s Naturopathy(陶向辉,薛丽霞,刘纯.中国民间疗法),2020,28(14):54-56.
Zhao W M.Lishizhen Med. Mater. Med. Res. (赵为民.时珍国医国药),2011,22(11):2811-2812.
Han W N,Han G,Xu Q Z,Xu Y.World J. Integrated Tradit. Western Med. (韩万年,韩光,徐全中,徐阳.世界中西医结合杂志),2007,2(suppl):113-114.
Cai B,Cheng B D,Qiang J H.Drugs Clin. (蔡波,成百朵,强建红.现代药物与临床),2016,31(9):1399-1402.
Liang C.J. Changchun Univ. Chin. Med. (梁成.长春中医药大学学报),2011,27(5):793-794.
Chen J Y,Jiang W W,He F L,Mo G Q,Guo Z H,Wang X D,Wu Q H,Cao H Y.China J. Chin. Mater. Med. 陈家艺,江伟雯,何风雷,莫国强,郭钟慧,王笑丹,吴清和,操红缨.中国中药杂志),2015,40(15):3059-3062.
Lian Q W,He F L,Mo G Q,Guo Z H,Wang X D,Fan P L,Wu Q H,Cao H Y,Huang P.J. Guangdong Pharm. Univ. (练庆旺,何风雷,莫国强,郭钟慧,王笑丹,范平龙,吴清和,操红缨,黄萍.广东药学院学报),2015,31(2):215-218.
Li G J,Xu Z D,Liu Y F,Li C H.J. Chin. Med. Mater. (李国驹,许招懂,刘袁芳,李灿辉.中药材),2006,29(4):365-367.
He C D,Chen Z Q,Xu Z X,Dai B Y.Strait Pharm. J. (何承队,陈振铨,许则省,戴碧怡.海峡药学),2022,34(2):75-78.
Wang X Q,Lü W S,Lin T.Tradit. Chin. Drug Res. Clin. Pharm. (王秀芹,吕渭升,林彤.中药新药与临床药理),2016,27(6):855-859.
Hu W J,Fu J,Tang X Y,Wang Y.J. Guangdong Pharm. Univ. (胡伟杰,符健,汤小燕,王岩.广东药学院学报),2016,32(3):330-334.
Niu X L,Zhang T P,Shi H,Zhang W.J. Hebei Tradit. Chin. Med. Pharm. (牛秀丽,张天鹏,石红,张旺.河北中医药学报),2015,30(2):58-60.
Chen L.Jiangxi J. Tradit. Chin. Med. (陈乐.江西中医药),2013,44(361):59-60.
Chen X M,Zhao C.Asia-Pac. Tradit. Med. (陈霞明,赵成.亚太传统医药),2013,9(6):44-45.
Adefegha S A,Oboh G,Ejakpovi I I,Oyeleye S I.Com. Clin. Pathol.,2015,24(6):1579-1585.
Ajiboye T O,Habibu R S,Saidu K.MicrobiologyOpen,2017,6(4):e472.
Tsao S M,Hsia T C,Yin M C.Nutr. Cancer,2014,66(8):1331-1341.
Winter A N,Brenner M C,Punessen N.Oxid. Med. Cell. Longevity,2017:6297080.
Kakkar S,Bais S.ISRN Pharm.,2014:952943.
Zhan L,Meng N Q,Nong J A.J. Clin. Tissue Eng. Res. (占龙,孟农钦,农桔安.中国组织工程研究),2020,24(8):1149-1154.
Zheng X H,Yang J,Yang Y H.J. Chin. Hosp. Pharm. (郑雪花,杨君,杨跃辉.中国医院药学杂志),2017,37(1):94-98.
Zhang C Y,Guo L L,Wang J.Chin. J. Exp. Tradit. Med. Formulae(张翠英,郭丽丽,王阶.中国实验方剂学杂志),2013,19(23):338-342.
0
浏览量
7
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构